To be honest, I was feeling a little impatient earlier in the week (mostly due to work-related news), then reminded myself:
- excellent p2 data on small dose
- shortcut to market (EU - small p2b, same endpoints as p2)
- fantastic broker coverage / insto support
- fantastic feedback from leading expert (Voit)
- Charmaine jumping on the board
- tiny market cap (~$100M) vs addressable market (many times that per-annum)
- huge unmet need in non-ambulant DMD boys
- potential to help younger/ambulant boys too (Voit confident)
- potential broad range of applications (other muscular dystrophies + general inflammatory-related conditions)
- FDA: happy with endpoints, we're applying for fast track designation + tox study can be done in parallel
- short term news incoming (EU PIP feedback, additional indications)
- potential to become a platform drug
... I ended up going from feeling slightly impatient to happily buying more.
Good luck guys!
Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US, page-99
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |